Mallinckrodt Pharmaceuticals

The Global Medical Isotope Market was valued at USD 5.66 billion in 2023 and is projected to reach USD 12.15 billion by 2032, growing at a CAGR of 8.87% driven by increased applications in diagnostics and therapy, particularly in cancer treatment. Key isotopes include technetium-99m, iodine-131, and lutetium-177. The market is influenced by advancements in nuclear medicine, imaging technologies, and personalized treatments, with challenges in supply chain and transportation due to radioactive nature. Major players include GE Healthcare, Jubilant Radiopharma, and Mallinckrodt Pharmaceuticals. North America dominates the market, while Asia-Pacific shows the fastest growth.

The Antihistamine Drugs Market is projected to grow from USD 279.74 million in 2024 to USD 381.39 million by 2030, driven by rising allergies, a growing geriatric population, and innovations in drug formulation. Key players include Johnson & Johnson, Sanofi, Pfizer, and Bayer. Challenges include market saturation, side effects, and stringent regulations.

The nanomedicine market was valued at USD 223.6 billion in 2023 and is projected to reach USD 634.2 billion by 2032, with a CAGR of 12.2%. This growth is driven by increased demand for advanced drug delivery systems and rising chronic disease incidence. North America leads the market, while Asia-Pacific is expected to grow the fastest.

The nanomedicine market, valued at USD 223.6 billion in 2023, is projected to reach USD 634.2 billion by 2032, driven by advanced drug delivery systems and rising chronic diseases. Key players include Johnson & Johnson, Mallinckrodt Pharmaceuticals, and Teva Pharmaceutical Industries. Recent developments include Novartis's nanoparticle-based ovarian cancer treatment and Merck's partnership with Stanford for immunotherapy research.

Immunotherapy less risky for non-small cell lung cancer patients with BMI under 28, while chemotherapy is optimal for those with BMI 28 or higher, according to Osaka Metropolitan University study.